GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引：0

作者：

Deodhar, Atul ^{[1
]}

Helliwell, Philip ^{[2
]}

Boencke, Wolf-Henning ^{[3
]}

Hsia, Elizabeth C. ^{[4
,5
,6
]}

Kollmeier, Alexa P. ^{[4
,5
]}

Subramanian, Ramanand A. ^{[4
,5
]}

Xu, Xie L. ^{[4
,5
]}

Sheng, Shihong ^{[4
,5
]}

Zhou, Bei ^{[4
,5
]}

Zazzetti, Federico ^{[7
]}

Ritchlin, Christopher ^{[8
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] Univ Leeds, Leeds, W Yorkshire, England

[3] Geneva Univ Hosp, Geneva, Switzerland

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Janssen Res & Dev LLC, San Diego, CA USA

[6] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA

[7] Janssen LATAM Med Affairs, Buenos Aires, DF, Argentina

[8] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

298

引用

页码：24 / 24

页数：1

共 50 条

[41] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 79 - 79
[42] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[43] Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naive patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study
Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf-Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Shawi, May
Yang, Ya-Wen
Sheng, Shihong
Agarwal, Prasheen
Helliwell, Philip S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB163 - AB163
[44] A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Mease, Philip J.
van der Heijde, Desiree
Ritchlin, Christopher T.
Cuchacovich, Raquel
Shuler, Catherine L.
Lee, Chin H.
Samanta, Suvajit
Lin, Chen-Yen
Gladman, Dafna D.
Vangerow, Harald
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[45] Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Mease, Philip
Chohan, Saima
Garcia Fructuoso, Ferran J.
Gottlieb, Alice
Chou, Richard C.
Mendelsohn, Alan
Ballerini, Rocco
Luggen, Michael E.
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[46] CLINICAL AND RADIOGRAPHIC EFFICACY OF SARILUMAB PLUS METHOTREXATE IN BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INTERNATIONAL STUDY
van der Heijde, D.
Genovese, M. C.
Fan, C.
Fiore, S.
Decktor, D. L.
Fleischmann, R.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 722 - 722
[47] Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
Mease, Philip J.
Gladman, Dafna D.
Deodhar, Atul
McGonagle, Dennis G.
Nash, Peter
Boehncke, Wolf-Henning
Gottlieb, Alice
Xu, Xie L.
Xu, Stephen
Hsia, Elizabeth C.
Karyekar, Chetan S.
Helliwell, Philip S.
RMD OPEN, 2020, 6 (02):
[48] A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis
Mease, Philip
van der Heijde, Desiree
Ritchlin, Christopher
Cuchacovich, Raquel
Shuler, Catherine
Lin, Chen-Yen
Vangerow, Harald
Samanta, Suvajit
Lee, Chin
Gladman, Dafna
JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1169 - 1169
[49] Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies
McGonagle, Dennis
McInnes, Iain
Deodhar, Atul
Schett, Georg
Mease, Philip
Shawi, May
Kafka, Shelly
Karyekar, Chetan
Kollmeier, Alexa
Hsia, Elizabeth
Xu, Xie
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Ritchlin, Christopher
Rahman, Proton
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[50] EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES
Mcgonagle, D.
Mcinnes, I.
Deodhar, A.
Schett, G.
Mease, P. J.
Shawi, M.
Kafka, S.
Karyekar, C.
Kollmeier, A.
Hsia, E. C.
Xu, X. L.
Sheng, S.
Agarwal, P.
Zhou, B.
Ritchlin, C. T.
Rahman, P.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1697 - 1697

← 1 2 3 4 5 →